JAGX Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of 33.68%. Jaguar Health, Inc.'s return on equity of -524.57% beat Merck & Co., Inc.'s return on equity of 39.63%.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2218.18%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.92 which suggests that it could grow by 4.99%. Given that Jaguar Health, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Jaguar Health, Inc. is more attractive than Merck & Co., Inc..

Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.21% to investors and pays a quarterly dividend of $0.81 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Jaguar Health, Inc.'s net income of -$9.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.09x versus 3.98x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -19.69%. Jaguar Health, Inc.'s return on equity of -524.57% beat Moderna, Inc.'s return on equity of -30.18%.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2218.18%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Jaguar Health, Inc. has higher upside potential than Moderna, Inc., analysts believe Jaguar Health, Inc. is more attractive than Moderna, Inc..

Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Jaguar Health, Inc.'s net income of -$9.6M is higher than Moderna, Inc.'s net income of -$200M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.09x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -255.85%. Jaguar Health, Inc.'s return on equity of -524.57% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2218.18%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Jaguar Health, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Jaguar Health, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Jaguar Health, Inc.'s net income of -$9.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.09x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of --. Jaguar Health, Inc.'s return on equity of -524.57% beat Palatin Technologies's return on equity of --.

Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2218.18%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Jaguar Health, Inc., analysts believe Palatin Technologies is more attractive than Jaguar Health, Inc..

Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Palatin Technologies quarterly revenues of --. Jaguar Health, Inc.'s net income of -$9.6M is higher than Palatin Technologies's net income of --. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.09x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.